Onco3R 治疗学显示3名癌症药物候选人的临床预科结果很有希望,推动他们到2026年年中接受临床试验。 Onco3R Therapeutics showed promising preclinical results for three cancer drug candidates, advancing them toward clinical trials by mid-2026.

Onco3R 治疗学在2025年AACR-NCI-EORTC专题讨论会上为三个肿瘤方案提供了临床预科数据,显示G-012、选择性FGFR3抑制剂G-141、在SMARCA4-变异致癌中有效的SMARCA2抑制剂SMARCA2、以及具有高能度和缩短居住时间的新型P53 Y220C再生器的可喜成果。 Onco3R Therapeutics presented preclinical data for three oncology programs at the 2025 AACR-NCI-EORTC Symposium, showing promising results for G-012, a selective FGFR3 inhibitor, G-141, a SMARCA2 inhibitor effective in SMARCA4-mutant cancers, and novel P53 Y220C reactivators with high potency and improved residence time. 该公司报告说,抗瘤活性强,安全性良好,使每个候选药物都进入临床开发,预计到2026年中期将进行IND支持研究. The company reported strong anti-tumor activity and favorable safety profiles, advancing each candidate toward clinical development, with IND-enabling studies expected by mid-2026. 这些数据支持Onco3R利用基于结构的设计和AI开发有针对性的治疗方法的管道进度。 The data supports Onco3R’s pipeline progress using structure-based design and AI to develop targeted therapies.